mAb Beta-53

An anti-SARS-CoV-2 monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status


Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

mAb Beta-53 is a monoclonal antibody neutralizing SARS-CoV-2 identified in a memory B cell of a COVID-19 convalescent patient who had been infected with the Beta variant of SARS-CoV-2 (Liu et al., 2022). mAb Beta-53 neutralizes also other SARS-CoV-2 variants in vitro, including Alpha, Gamma, Delta (Liu et al., 2022), and Omicron (Dejnirattisai et al., 2022).


mAb β53


Supporting references

Link Tested on Impact factor Notes Publication date
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Spike protein ACE2 RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance
sera from vaccinated or convalescent individuals; VeroE6/TMPRSS2 cells; SARS-CoV-2 (various strains) 41.58

Neutralizes Omicron variant in vitro. 

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
Spike protein Spike variant Cryo-EM Crystallization Novel compound Biophysical assay Protein factor Animal model In vitro Mechanism Antibody Screening
in vitro biophysical assay; crystallization; cryo-EM; plasma of COVID-19 (Beta strain) convalescent patients; Vero cells; VeroE6/TMPRSS2 cells; Vero-hACE2-TMPRSS2 cells; K18-hACE C57BL/6J mice; SARS-CoV-2 (various strains) 21.02

mAb Beta-53 neutralizes various SARS-CoV-2 variants in vitro, including Alpha, Gamma, Delta.